Organon & Co. (OGN) Projected to Post Earnings on Thursday

Key Points

• Organon & Co. is expected to report its Q3 2025 earnings on October 30th, with analysts predicting earnings of $0.93 per share and revenue of $1.5669 billion.
• In the previous quarter, the company reported earnings of $1.00 per share, exceeding expectations and generating revenue of $1.59 billion, albeit down 0.8% from the previous year.
• The company has a debt-to-equity ratio of 11.98 and a market capitalization of $2.33 billion, with institutional investors owning approximately 77.43% of its stock.

Organon & Co. (NYSE:OGN - Get Free Report) is anticipated to post its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Organon & Co. to post earnings of $0.93 per share and revenue of $1.5669 billion for the quarter. Organon & Co. has set its FY 2025 guidance at EPS.Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.06. The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The company's quarterly revenue was down .8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.12 earnings per share. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Stock Performance

Shares of OGN opened at $8.95 on Thursday. The company has a debt-to-equity ratio of 11.98, a quick ratio of 1.13 and a current ratio of 1.65. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of 3.33, a PEG ratio of 0.81 and a beta of 0.63. The company's 50 day simple moving average is $9.93 and its 200 day simple moving average is $9.95. Organon & Co. has a 1 year low of $8.01 and a 1 year high of $19.05.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Investors of record on Friday, August 15th were paid a dividend of $0.02 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. Organon & Co.'s dividend payout ratio is presently 2.97%.

Hedge Funds Weigh In On Organon & Co.

Large investors have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in Organon & Co. during the second quarter worth approximately $107,000. Gamco Investors INC. ET AL acquired a new stake in shares of Organon & Co. in the second quarter worth $119,000. Cresset Asset Management LLC acquired a new stake in shares of Organon & Co. in the second quarter worth $134,000. Humankind Investments LLC increased its position in shares of Organon & Co. by 50.8% in the second quarter. Humankind Investments LLC now owns 17,060 shares of the company's stock worth $165,000 after acquiring an additional 5,748 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its position in shares of Organon & Co. by 33.1% in the second quarter. Canada Pension Plan Investment Board now owns 21,700 shares of the company's stock worth $210,000 after acquiring an additional 5,400 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a "sell (d+)" rating on shares of Organon & Co. in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.